- Home
- RCUS vs CMRE Comparison
RCUS vs CMRE Comparison
Compare RCUS & CMRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RCUS
- CMRE
- Stock Information
- Founded
- RCUS 2015
- CMRE 1974
- Country
- RCUS United States
- CMRE Monaco
- Employees
- RCUS N/A
- CMRE N/A
- Industry
- RCUS Biotechnology: Pharmaceutical Preparations
- CMRE Marine Transportation
- Sector
- RCUS Health Care
- CMRE Consumer Discretionary
- Exchange
- RCUS Nasdaq
- CMRE Nasdaq
- Market Cap
- RCUS 1.2B
- CMRE 1.3B
- IPO Year
- RCUS 2018
- CMRE 2010
- Fundamental
- Price
- RCUS $12.20
- CMRE $12.09
- Analyst Decision
- RCUS Buy
- CMRE Hold
- Analyst Count
- RCUS 8
- CMRE 1
- Target Price
- RCUS $20.71
- CMRE $13.00
- AVG Volume (30 Days)
- RCUS 772.4K
- CMRE 487.9K
- Earning Date
- RCUS 11-05-2025
- CMRE 10-31-2025
- Dividend Yield
- RCUS N/A
- CMRE 3.82%
- EPS Growth
- RCUS N/A
- CMRE N/A
- EPS
- RCUS N/A
- CMRE 2.37
- Revenue
- RCUS $262,000,000.00
- CMRE $2,085,912,000.00
- Revenue This Year
- RCUS N/A
- CMRE N/A
- Revenue Next Year
- RCUS N/A
- CMRE N/A
- P/E Ratio
- RCUS N/A
- CMRE $4.55
- Revenue Growth
- RCUS 6.07
- CMRE 56.37
- 52 Week Low
- RCUS $6.50
- CMRE $6.02
- 52 Week High
- RCUS $18.98
- CMRE $12.12
- Technical
- Relative Strength Index (RSI)
- RCUS 75.43
- CMRE 71.88
- Support Level
- RCUS $10.40
- CMRE $11.26
- Resistance Level
- RCUS $11.84
- CMRE $12.12
- Average True Range (ATR)
- RCUS 0.54
- CMRE 0.31
- MACD
- RCUS 0.16
- CMRE -0.00
- Stochastic Oscillator
- RCUS 98.35
- CMRE 97.03
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.
About CMRE Costamare Inc. $0.0001 par value
Costamare Inc is an international owner and operator of containerships and dry bulk vessels. The company charter its containerships to the liner companies, providing transportation of containerized cargoes. It charter its dry bulk vessels to a wide variety of customers, providing transportation for dry bulk cargoes. The company's fleet of vessels includes Cosco Guangzhou, Cosco Ningbo, Cosco Yantian, Vantage, Valor, Valiant, Maersk Kobe, and among others. Costamare provides services to ocean carriers that demand a high standard of safety and reliability. It generates a majority of its revenue from the United States of America.